永安药业今日上涨3.70%，全天换手率35.25%，成交额10.15亿元，振幅15.09%。龙虎榜数据显示，机构 净卖出20.25万元，营业部席位合计净买入288.69万元。 近半年该股累计上榜龙虎榜9次，上榜次日股价平均涨2.55%，上榜后5日平均跌1.47%。 资金流向方面，今日该股主力资金净流入5442.80万元，其中，特大单净流入3869.52万元，大单资金净 流入1573.28万元。近5日主力资金净流入3911.06万元。（数据宝） 永安药业5月7日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 广发证券股份有限公司郑州农业路证券营业部 | 1814.51 | 6.18 | | 买二 | 机构专用 | 1543.23 | 689.34 | | 买三 | 中国银河证券股份有限公司大连人民路证券营业部 | 1317.51 | 60.21 | | 买四 | 中国国际金融股份有限公司上海分公司 | 1198.02 | 323.18 | | 买五 | 中信建投证券股份有限公司上海营口路证券营业部 ...

Core Viewpoint - The investigation of the actual controller of Yong'an Pharmaceutical, Chen Yong, comes amid unusual stock price fluctuations, raising concerns about the company's governance and financial health [2][3]. Company Investigation - Yong'an Pharmaceutical announced that its actual controller and chairman, Chen Yong, is under investigation by the Hubei Province Hefeng County Supervisory Committee and has been detained [2][3]. - Chen Yong holds 21.54% of Yong'an Pharmaceutical's shares as of the end of March this year [2][3]. - The company did not disclose the specific reasons for Chen's investigation, stating that other board members are performing their duties normally and that the company's control and operations remain unaffected [3][4]. Stock Price Fluctuations - The stock price of Yong'an Pharmaceutical experienced significant volatility, with a surge of nearly 60% over seven trading days, attributed to rumors of soaring taurine prices [2][6]. - The stock reached a peak of 14.34 CNY per share before declining to 11.62 CNY per share following the company's clarification that the rumors were untrue [6][7]. Financial Performance - Yong'an Pharmaceutical's revenue has been declining for three consecutive years, with a net loss of 4.367 million CNY reported in the first quarter of this year [2][8]. - The company's revenues for 2022, 2023, and 2024 were 1.462 billion CNY, 973 million CNY, and 839 million CNY, respectively, with net profits of 140 million CNY, -12 million CNY, and 6.2 million CNY [8]. Legal Challenges - The company is also facing long-term challenges from a cross-border lawsuit regarding patent infringement related to its taurine products [9]. - A court ruling in February 2024 found that Yong'an Pharmaceutical did not infringe on the patents claimed by VITAWORKS IP, LLC, but the case is still ongoing due to an appeal [9].

近半年该股累计上榜龙虎榜8次，上榜次日股价平均涨2.39%，上榜后5日平均跌4.10%。 资金流向方面，今日该股主力资金净流出3207.58万元，其中，特大单净流出2917.08万元，大单资金净 流出290.50万元。近5日主力资金净流出1.52亿元。（数据宝） 永安药业5月6日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 海通证券股份有限公司保定东风东路证券营业部 | 127.01 | 0.00 | | 买二 | 中泰证券股份有限公司潍坊东风西街证券营业部 | 116.20 | 0.00 | | 买三 | 国投证券股份有限公司揭阳分公司 | 100.40 | 0.00 | | 买四 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | 78.67 | 0.00 | | 买五 | 东方财富证券股份有限公司上海徐汇区云锦路证券营业 部 | 69.26 | 0.00 | | 卖一 | 东莞证券股份有限公司厦门分公司 | 0.12 | 929.60 | | 卖二 | 华泰证 ...

Group 1 - The core issue is that Chen Yong, the actual controller and chairman of Yong'an Pharmaceutical, has been placed under investigation and detention by the Hekou County Supervisory Committee, which may impact the company's operations and investor confidence [1][4]. - Yong'an Pharmaceutical is the 11th listed company in the A-share market to disclose that a senior executive has been detained this year, indicating a trend of increased regulatory scrutiny in the capital market [2][9]. - The company has experienced significant fluctuations in its financial performance, with a reported revenue of 973 million yuan in 2023, a year-on-year decrease of 33.48%, and a net profit loss of 75.99 million yuan, marking a 162.11% decline [6][8]. Group 2 - Yong'an Pharmaceutical primarily engages in the research, production, and sales of three types of products: taurine, health foods, and special dietary foods, with taurine being its largest segment, holding approximately 50% of the global market share [6][8]. - The company's stock price fell to the limit down on May 6, following the announcement of Chen Yong's investigation, reflecting a loss of investor confidence [5]. - The recent trend of high-level executives being detained may be attributed to increased regulatory enforcement and the growing operational pressures faced by listed companies, which could lead to governance issues [10].

证券代码：002365 证券简称：永安药业 公告编号：2025-33 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业，证 券代码：002365）股票交易价格于 2025 年 4 月 30 日、2025 年 5 月 6 日连续两 个交易日内日收盘价格跌幅偏离值累计超出 20%，根据深圳证券交易所的有关规 定，属于股票交易异常波动的情况。 二、公司关注、核实情况说明 针对公司股票交易异常波动，公司董事会对公司相关事项进行了核实，现 就有关情况说明如下： （一）经核查，公司前期披露的信息不存在需要更正、补充之处。 （二）公司于 2025 年 5 月 6 日披露了《关于公司实际控制人、董事长被留 置的公告》（公告编号 2025-31），公司实际控制人、董事长陈勇先生被立案调 查并实施留置，截至本公告披露日，公司暂未知悉上述事项的进展及结论，暂未 收到有权机关对公司的任何调查或者配合调查文件。公司具有完善的组织结构和 规范的治理体系，目前公司生产经营活动正常，公司其他董事、监 ...

最后再强调一句，我是帮主郑重，专注中长线投资20年，以后会经常跟大家唠唠市场里的这些事儿，帮大伙把投资的路看得更清楚。记住了，投资路上别贪 心，合规和稳健才是硬道理。今天这事儿就聊到这儿，咱们下回接着唠！ 不过啊，帮主觉得这事儿有点蹊跷。不知道大家还记得不，就在4月21号到29号那阵子，永安药业7个交易日里整整来了5个涨停板，股价跟坐了火箭似的往 上窜。现在回头看，这波涨停会不会和董事长被查有啥关联呢？是不是有人提前知道了消息在搞动作？这些都得等监管部门进一步调查才能水落石出。 作为中长线投资者，咱得明白一个道理：买股票就是买公司，要是公司的当家人出了问题，那基本面可就像建在沙滩上的房子，说塌就塌。尤其是这种突然 的股价异动背后，往往藏着不少风险。咱选股的时候，得多留个心眼，看看公司治理是否规范，有没有合规隐患，别光盯着短期涨幅就往里冲。 现在这事儿给咱们提了个醒：资本市场不是法外之地，不管多大的老板，只要触犯了规则，就得接受调查。咱们普通投资者啊，还是得把眼光放长远，远离 那些靠炒作起来的"妖股"，多关注真正有业绩支撑、管理规范的企业。 各位朋友大家好，我是帮主郑重，做了20年财经记者的中长线投资者。今天咱 ...

潜江永安药业股份有限公司（以下简称"公司"）第七届董事会第七次临时 会议的会议通知于 2025 年 5 月 5 日以书面、电话、传真、电子邮件等形式送达 公司全体董事，会议于 2025 年 5 月 6 日在公司会议室以通讯方式召开，本次会 议应参与审议表决董事 6 人，实际参与审议表决董事 5 人，缺席董事 1 人（董事 长陈勇先生因暂不能正常履职，缺席本次会议），参会全体董事同意豁免本次会 议通知期限，会议由公司半数以上董事推举董事陈子笛先生主持，会议的召开符 合《公司法》、《公司章程》及《董事会议事规则》的规定，会议以书面记名投 票方式进行表决，通过了如下决议： 审议通过《关于推举公司董事、常务副总经理代为履行董事长职责的议案》 表决结果：同意 5 票，反对 0 票，弃权 0 票。 鉴于公司董事长陈勇先生暂无法履行董事长职责，详见公司于 2025 年 5 月 6 日披露的《关于公司实际控制人、董事长被留置的公告》（公告编号： 2025-31），为了保证公司董事会正常运作和经营决策的顺利开展，维护公司经 营和治理的稳定性，董事会同意由公司董事、常务副总经理陈子笛先生在此期间 代为履行董事长的职责。 上述事项 ...

Group 1 - The company, Qianjiang Yong'an Pharmaceutical Co., Ltd., announced that its actual controller and chairman, Chen Yong, is under investigation and has been detained, leading to a stock price drop and a total market value of 3.424 billion yuan [1] - The company was listed in March 2010 and primarily engages in the research, production, and sales of taurine products, epoxy ethane, and health-related products, as well as investments in the health sector [2] - The company's revenue for the years 2022, 2023, 2024, and the first quarter of 2025 was 1.46245 billion yuan, 972.89 million yuan, 838.81 million yuan, and 171.15 million yuan respectively, with net profit attributable to the parent company showing fluctuations [2] Group 2 - Chen Yong, born in January 1959, is currently 66 years old and received a salary of 2.5741 million yuan for the year 2024 [2] - As of March 31, 2025, Chen Yong directly holds 21.54% of the company's shares, with a market value of 737.5 million yuan [2]

永安药业（002365）一字跌停，公司实际控制人、董事长陈勇被立案调查并实施留置。 ...

Group 1 - Heng Rui Pharmaceutical has officially passed the Hong Kong Stock Exchange listing hearing, with the potential to be listed as early as May [1] - The listing represents a significant step in Heng Rui's internationalization strategy, following its IPO in the A-share market [1] - The company aims to leverage the larger growth opportunities in overseas markets as part of its "innovation + internationalization" dual-driven strategy [1] Group 2 - Neuralink's brain-computer interface device Link has received FDA "breakthrough device" designation, aimed at providing communication solutions for patients with severe speech impairments [2] - This designation will expedite the review process, marking a significant advancement for Neuralink in the brain-computer interface field [2] - However, this certification does not equate to market approval, and further clinical validation and safety assessments are required [2] Group 3 - Novo Nordisk's oral version of the weight loss drug Wegovy has had its application accepted by the FDA, with a decision expected in Q4 [3] - If approved, it will be the first oral GLP-1 receptor agonist for chronic weight management globally, potentially enhancing Novo Nordisk's competitive position in the weight loss market [3] - The oral formulation addresses issues of injection adherence among patients, indicating a broad market opportunity if approved [3] Group 4 - Xianju Pharmaceutical has received an administrative penalty of 195 million yuan for engaging in price-fixing agreements that restricted competition in the market for dexamethasone phosphate raw materials [4] - This significant fine reflects the increasing regulatory scrutiny and enforcement against anti-competitive practices in the pharmaceutical sector [4] - The penalty is expected to have a substantial negative impact on Xianju's short-term performance and highlights weaknesses in the company's compliance framework [4] Group 5 - Yong'an Pharmaceutical's chairman Chen Yong is under investigation and has been detained, although the company states that its operations and management remain stable [5] - The investigation may affect the market's perception of the company's credibility and management stability [5] - Despite assurances of normal operations, there may be short-term pressure on the company's stock price due to the uncertainty surrounding the investigation [5]